,使

Chien-Yi Liao1,2, Yuh-Min Chen3,4, Yu-Te Wu5,6

  • 1Department of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, No. 155, Sec. 2, Linong Street, Beitou District, Taipei, 112, Taiwan.

概括

结合成像生物标志物和临床数据的新模型预测了接受免疫疗法 (IO) 的肺癌 (LC) 患者的无进展生存期 (PFS). 这种方法有助于个性化治疗,改善晚期LC的治疗结果.

相关概念视频

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...